» Articles » PMID: 36438727

Assessing Causal Relationships Between Sarcopenia and Nonalcoholic Fatty Liver Disease: A Bidirectional Mendelian Randomization Study

Overview
Journal Front Nutr
Date 2022 Nov 28
PMID 36438727
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Sarcopenia has been demonstrated to be closely associated with nonalcoholic fatty liver disease (NAFLD). However, whether there are causal relationships between sarcopenia and NAFLD remains undetermined. Here, we aim to address the question using a two-sample bidirectional Mendelian randomization (MR) analysis approach.

Methods: We performed a two-sample bidirectional MR study using summary-level data from genome-wide association studies (GWAS) of the whole body lean mass ( = 38,292), appendicular (arms and legs) lean mass ( = 28,330), and NAFLD (1,483 biopsy-proven NAFLD cases and 17,781 controls). We first conducted MR analysis with five single nucleotide polymorphisms (SNPs) as genetic instruments for whole body lean mass and three SNPs as instruments for appendicular lean mass to estimate the causal effect of genetically predicted sarcopenia on the risk of NAFLD using the inverse-variance weighted (IVW) method. Then we performed reverse MR analysis with four SNPs as instruments to examine the causality of genetically predicted NAFLD with whole body lean mass and appendicular lean mass. Further sensitivity analysis was conducted to testify the reliability of the MR results.

Results: Genetic predisposition to decreased whole body lean mass was not associated with NAFLD [IVW-random effects, odds ratio (OR) = 1.054, 95%CI: 0.750-1.482, = 0.761]. Similar results were observed using genetic instruments of appendicular lean mass (IVW-random effects, OR = 0.888, 95%CI: 0.386-2.042, = 0.780). Reverse MR analysis revealed that genetically predicted NAFLD using four genetic instruments was not associated with whole body lean mass (IVW, β = -0.068, 95%CI: -0.179 to 0.043, = 0.229) and appendicular lean mass (IVW, β = -0.020, 95%CI: -0.092 to 0.051, = 0.574). MR analyses using other methods and sensitivity analysis showed consistent results.

Conclusion: These results suggested no causal relationships between sarcopenia and NAFLD, indicating that sarcopenia may not be directly involved in the pathogenesis of NAFLD and vice versa.

Citing Articles

Causal relationship between non-alcoholic fatty liver disease and sarcopenia: a bidirectional Mendelian randomization study.

Chen M, Liu J, Xia X, Wang Y, Zheng H Front Med (Lausanne). 2024; 11:1422499.

PMID: 39359931 PMC: 11445014. DOI: 10.3389/fmed.2024.1422499.


Exploring causal effects of sarcopenia on risk and progression of Parkinson disease by Mendelian randomization.

Wang T, Geng J, Zeng X, Han R, Huh Y, Peng J NPJ Parkinsons Dis. 2024; 10(1):164.

PMID: 39198455 PMC: 11358304. DOI: 10.1038/s41531-024-00782-3.


Low muscle quality index is associated with increased risk of advanced fibrosis in adult patients with nonalcoholic fatty liver disease: NHANES 2011-2014.

Tantai X, Ran Q, Wen Z, Tuo S, Liu N, Dai S Sci Rep. 2024; 14(1):19883.

PMID: 39191842 PMC: 11349751. DOI: 10.1038/s41598-024-71096-w.


Sarcopenia-related traits and 10 digestive system disorders: insight from genetic correlation and Mendelian randomization.

Yang T, Liu Z, Xiu M, Qing X, Liu S, Xiao W Front Public Health. 2024; 12:1412842.

PMID: 39050602 PMC: 11267997. DOI: 10.3389/fpubh.2024.1412842.


The causal effects of intelligence and fluid intelligence on Parkinson's disease: a Mendelian randomization study.

Jing C, Zhong X, Min X, Xu H Front Aging Neurosci. 2024; 16:1388795.

PMID: 38846742 PMC: 11153853. DOI: 10.3389/fnagi.2024.1388795.


References
1.
Bowden J, Davey Smith G, Haycock P, Burgess S . Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016; 40(4):304-14. PMC: 4849733. DOI: 10.1002/gepi.21965. View

2.
Anstee Q, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D . Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J Hepatol. 2020; 73(3):505-515. DOI: 10.1016/j.jhep.2020.04.003. View

3.
Cleasby M, Jamieson P, Atherton P . Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J Endocrinol. 2016; 229(2):R67-81. DOI: 10.1530/JOE-15-0533. View

4.
Brion M, Shakhbazov K, Visscher P . Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2013; 42(5):1497-501. PMC: 3807619. DOI: 10.1093/ije/dyt179. View

5.
Shaw S, Dennison E, Cooper C . Epidemiology of Sarcopenia: Determinants Throughout the Lifecourse. Calcif Tissue Int. 2017; 101(3):229-247. PMC: 5544114. DOI: 10.1007/s00223-017-0277-0. View